H.P. Acthar Gel in ALS

Phase 3, randomised, double-blind trial of repository corticotropin injection in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 36 weeks, Number of Participants Experiencing an Adverse Event During the Treatment Period at 36 weeks and 1 more. Started Jun 2017; status: terminated.